Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Pfizer

Status: Completed

Conditions: Kidney Neoplasms

Treatments: Drug: sunitinib; Drug: axitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT04669366

A6181234

RENCOMP3 (Other Identifier)

Details and patient eligibility

About

The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.

Enrollment: 1,205 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. all patients aged ≥ 18 years with at least one filled prescription of an oral targeted therapy relevant for treating mRCC registered in the Swedish Prescribed Drug Register (PDR) between July 1st 2005 and June 30th 2020. The Anatomical Therapeutic Chemical (ATC) codes for the oral drugs relevant for treating mRCC are the following: L01XE04 (sunitinib), L01XE05 (sorafenib), L01XE11 (pazopanib), L01XE17 (axitinib), L01XE10 (everolimus), L01XE26 (cabozantinib), L01XE34 (tivozantib), L01XE29 (lenvatinib).
2. The patients identified in the PDR that also are identified in the SCR with the International Classification of Diseases and Related Health Problems (ICD)-7 diagnosis codes I800 or I809 and ICD-10 codes C64.0 and C64.9 from January 1st 2000 until December 31st 2019;excluding ICD-7 code I801 (cancer of the renal pelvis) will be included in the analysis set.

Exclusion criteria

Patients with ICD-7 code I801 will be excluded

Trial design

1,205 participants in 1 patient group

Patients in Sweden with metastatic renal cell carcinoma

Description:

The cohort of patients with metastatic renal cell carcinoma in Sweden

Treatment:

Drug: axitinib

Drug: sunitinib